PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy

Virchows Archiv

Volumn 461, Issue 2, 2012, Pages 129-139

  Barbareschi, Mattia ^a   Cuorvo, Lucia Veronica ^a   Girlando, Salvatore ^a   Bragantini, Emma ^a   Eccher, Claudio ^b   Leonardi, Elena ^a   Ferro, Antonella ^a   Caldara, Alessia ^a   Triolo, Renza ^a   Cantaloni, Chiara ^a   Decarli, Nicola ^a   Galligioni, Enzo ^a   Dalla Palma, Paolo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

^b FONDAZIONE BRUNO KESSLER   (Italy)

Author keywords

Breast cancer; Her2; PI3KCA mutation; PTEN loss; Trastuzumab

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PI3KCA PROTEIN; PROGESTERONE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ABLATION THERAPY; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; DNA EXTRACTION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE LOSS; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARIAN ABLATION; PRIORITY JOURNAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; PTEN PHOSPHOHYDROLASE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS;

EID: 84867398119     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1267-2     Document Type: Article

References (43)

1. Clifford A, Hudis MD (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51
2. Bailey TA, Luan H, Clubb RJ, Naramura M, Band V, Raja SM, Band H (2011) Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. J Carcinog 10:28
3. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132-4141 (Pubitemid 34791085)
4. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G (2003) Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30 (5 Suppl 16):93-104 (Pubitemid 37433400)
5. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647-1656
6. Lopez-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL (2010) PI3K pathway activation in breast cancer is associated with the basallike phenotype and cancer-specific mortality. Int J Cancer 126:1121-1131
7. Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del GM, Ferro A, Dalla PP, Galligioni E, Marchetti A (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13:6064-6069 (Pubitemid 350075063)
8. Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME (2011) PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Canc Res Treat 129:635-643
9. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S (2007) Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 13:408-414 (Pubitemid 46225343)
10. Perez-Tenorio G, Berglund F, Esguerra MA, Nordenskjold B, Rutqvist LE, Skoog L, Stal O (2006) Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer. Int J Oncol 28:1031-1042
11. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, Van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT (2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:6084-6091
12. Lerma E, Catasus L, Gallardo A, Peiro G, Alonso C, Aranda I, Barnadas A, Prat J (2008) Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas. Virchows Arch 453:133-139
13. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:2554-2559 (Pubitemid 40490050)
14. Li SY, Rong M, Grieu F, Iacopetta B (2006) PIK3CA mutations in breast cancer are associated with poor outcome. Breast Canc Res Treat 96:91-95
15. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D, Marchetti A (2007) PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 208:350-355 (Pubitemid 43210521)
16. Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti MA, Bardelli A (2008) PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 29:284-288 (Pubitemid 351240601)
17. Liedtke C, Cardone L, Tordai A, Yan K, Gomez HL, Figureoa LJ, Hubbard RE, Valero V, Souchon EA, Symmans WF, Hortobagyi GN, Bardelli A, Pusztai L (2008) PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Canc Res 10:R27
18. Tsutsui S, Inoue H, Yasuda K, Suzuki K, Higashi H, Era S, Mori M (2005) Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 68:398-404 (Pubitemid 41160970)
19. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F (2011) PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther 10:1093-1101
20. Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crino L (2009) EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 20:648-654
21. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, Van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Canc Cell 12:395-402 (Pubitemid 47539306)
22. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Canc Biol Ther 3:772-775 (Pubitemid 41351083)
23. Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, Tabone E, Puisieux A, Wang Q (2012) Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Canc Res Treat 132:23-39
24. Michelucci A, Di CC, Lami A, Collecchi P, Caligo A, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della RC, Stanta G, Bevilacqua G, Cavazzana A (2009) PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol 18:200-205
25. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J (2010) Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Canc Res Treat 119:379-390
26. Dupont JJ, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, Hackl W, Barrett JC, Gardner H (2011) PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 17:667-677
27. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15:1064-1069
28. Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Canc Res Treat 128:447-456
29. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX (2009) Ligandindependent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Canc Cell 15:429-440
30. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC (2011) Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:166-173
31. Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X (2011) PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Canc 11:11
32. Brunner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW (2011) The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Canc Res Treat 129:387-400
33. Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Canc Res 13:224
34. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:9221-9230
35. Cantaloni C, Tonini RE, Eccher C, Morelli L, Leonardi E, Bragantini E, Aldovini D, Fasanella S, Ferro A, Cazzolli D, Berlanda G, Dalla PP, Barbareschi M (2011) Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system. Appl Immunohistochem Mol Morphol 19:306-312
36. Barbareschi M, Girlando S, Mauri FM, Forti S, Eccher C, Mauri FA, Togni R, Dalla PP, Doglioni C (1994) Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 102:171-175 (Pubitemid 24320519)
37. Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla PP, Barbareschi M (2011) Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 6(Suppl 1):S7
38. Xu BH, Jiang ZF, Chua D, Shao ZM, Luo RC, Wang XJ, Liu DG, Yeo W, Yu SY, Newstat B, Preston A, Martin AM, Chi HD, Wang L (2011) Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients. Chin J Canc 30:327-335
39. Girlando S, Cuorvo LV, Bonzanini M, Morelli L, Amadori P, Dalla PP, Barbareschi M (2011) High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy. Int J Surg Pathol 8:173-176
40. Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13:5883-5888 (Pubitemid 47583915)
41. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu XY (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Canc Cell 18:160-170
42. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, DiGiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Jenny C, Chang JC (2005) Neoadjuvant Trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23:2460-2468 (Pubitemid 47050836)
43. Varchetta S, Gibelli L, Oliviero V, Nardini E, Gennari R, Gatti G, Silva LS, Villani N, Tagliabue E, Menard S, Costa A, Fannioni FF (2007) Element related to enterogenity of antibody-dependent cell cytotoxicity in patients under Trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67:11991-11999